Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00760955 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

A Phase 2 study of Diabetic Neuropathies, sponsored by Takeda.

Completed
Registry status
Phase 2
Development phase
338
Enrollment target
20
Study locations

NCT00760955 is a Phase 2 study of Diabetic Neuropathies that has completed, run by Takeda. The registered enrollment target is 338 participants, above the 286-participant average among 8 other Diabetic Neuropathies trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00760955, a Phase 2 study of Diabetic Neuropathies, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 2
Development phase
338 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the safety and effectiveness of TAK-583, once daily (QD), in the treatment of neuropathy caused by diabetes mellitus.

Conditions Studied

Diabetic Neuropathies

Interventions

  • DRUG Placebo
  • DRUG TAK-583

Study Locations (20)

Florida

  • - Largo
  • - Miami
  • - New Port Richey
  • - Palm Beach Gardens
  • - Sunrise
  • - West Palm Beach

California

  • - Huntington Beach
  • - La Jolla
  • - Los Angeles
  • - Pasadena
  • - Tustin

Arizona

  • - Mesa
  • - Peoria
  • - Phoenix
  • - Tucson

Arkansas

  • - Jonesboro

Georgia

  • - Decatur

Idaho

  • - Idaho Falls

Illinois

  • - Chicago

Massachusetts

  • - Boston

Trial Details

FieldValue
Enrollment Target 338 participants
Start Date 2006-09
Est. Completion 2008-02
Phase Phase 2

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00760955

The ClinicalTrials.gov registry entry for NCT00760955 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 286-participant average among 8 other Diabetic Neuropathies trials with a reported enrollment target (18% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Neuropathies appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00760955 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT00760955 about?

NCT00760955 is a clinical study titled "Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy". The purpose of this study is to determine the safety and effectiveness of TAK-583, once daily (QD), in the treatment of neuropathy caused by diabetes mellitus.

What is the current status of trial NCT00760955?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2006-09. Estimated completion is 2008-02.

What conditions does trial NCT00760955 study?

This clinical trial studies the following conditions: Diabetic Neuropathies.

What interventions are being tested in trial NCT00760955?

The interventions under investigation include: Placebo (DRUG), TAK-583 (DRUG).

Who is sponsoring clinical trial NCT00760955?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00760955 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Neuropathies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetic Neuropathies

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.